Biomerica (BMRA) vs Cytosorbents (CTSO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biomerica (BMRA) has outperformed Cytosorbents (CTSO) over the past year, losing 34.4% versus a loss of 80.9%. Over five years, BMRA leads with a -95.7% price change compared with -96.8% for CTSO. Cytosorbents is the larger company by market cap ($11.8 million vs $8.7 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRA | CTSO |
|---|---|---|
| Share price | $1.89 | $3.73 |
| Market cap | $8.69M | $11.75M |
| 1-day change | -0.53% | -3.62% |
| YTD return | -25.00% | -70.81% |
| 1-year return | -34.38% | -80.87% |
| 5-year return | -95.74% | -96.82% |
| Forward P/E | 4.85 | — |
| EPS (TTM) | $-1.30 | $-5.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.21 | $19.72 |
| 52-week low | $1.45 | $3.66 |
| Distance from 52-week high | -41.12% | -81.09% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1173.46% |
| Average volume | 70.88K | 12.45K |
| Shares outstanding | 4.60M | 3.15M |
| Employees | 50 | 129 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMRA has outperformed CTSO by 46.5 percentage points over the past year.
About Biomerica
BMRA stock →Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels.
Healthcare · Medical Devices · 50 employees
About Cytosorbents
CTSO stock →Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
Healthcare · Medical Devices · 129 employees
BMRA vs CTSO FAQ
Which is bigger, Biomerica or Cytosorbents?
Cytosorbents (CTSO) is larger, with a market capitalization of $11.75M compared with $8.69M for Biomerica (BMRA).
Which stock has performed better over the past year, BMRA or CTSO?
BMRA returned -34.38% over the past 12 months, compared with -80.87% for CTSO (price return, excluding dividends). Past performance does not predict future results.
Are Biomerica and Cytosorbents in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.